BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsCompany update

- Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount - New $400 million term loan priced at SOFR plus 5.50% - Debt has no scheduled amortization payments or required sweeps during the term prior to the Maturity Date of November 2, 2031

Related news

ARWRArrowhead Pharmaceuticals2026-10-14 11:30 EST

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

RCKTRocket Pharmaceuticals2026-10-06 20:12 EST

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

ETONEton Pharmaceuticals2026-11-02 11:50 EST

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

ETONEton Pharmaceuticals2026-11-04 21:30 EST

Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-11-07 21:15 EST

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

ARWRArrowhead Pharmaceuticals2026-11-04 12:30 EST

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

ARWRArrowhead Pharmaceuticals2026-11-03 21:00 EST

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

ARWRArrowhead Pharmaceuticals2026-10-27 15:36 EST

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Stock data

Close
57.46 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States